triazoles has been researched along with Foot Dermatoses in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (12.50) | 29.6817 |
| 2010's | 38 (67.86) | 24.3611 |
| 2020's | 11 (19.64) | 2.80 |
| Authors | Studies |
|---|---|
| Garoufalis, MG | 1 |
| Fukushima, S; Higuchi, S; Hiruma, M; Kano, R; Kashiwada-Nakamura, K; Kubo, M; Matsumoto, T; Noguchi, H; Satoh, T; Yaguchi, T | 1 |
| Lin, K; Lipner, SR | 1 |
| Hamedani, E; Harkless, L; Navarrete, R; Seun, J; Shofler, D; Thamby, R | 1 |
| Gupta, AK; Piguet, V; Shear, NH; Venkataraman, M | 1 |
| Eichenfield, LF; Elewski, B; Guenin, E; Gupta, AK; Pillai, R; Rosen, T; Sugarman, JL; Vlahovic, TC | 1 |
| Fujimoto, K; Mayumi, N; Otsuka, Y; Saeki, H; Yamaguchi, H | 1 |
| Eichenfield, LF; Elewski, B; Guenin, E; Gupta, AK; Pillai, R; Rosen, T; Stein Gold, L; Sugarman, JL; Vlahovic, TC | 1 |
| Cooper, EA; Gupta, AK | 1 |
| Anbalagan, N; Guenin, EP; Gupta, AK; Venkataraman, M | 1 |
| Abramovits, W; Guenin, EP; Gupta, AK; Venkataraman, M | 1 |
| Cook-Bolden, FE; Lin, T | 1 |
| Cantrell, W; Elewski, BE; Lin, T | 1 |
| Asao, K; Fukushima, S; Hirose, M; Hiruma, M; Ihn, H; Matsumoto, T; Noguchi, H | 1 |
| Bonhert, K; Dorizas, A; Sadick, NS | 1 |
| Fukushima, S; Hirose, M; Hiruma, M; Ihn, H; Matsumoto, T; Noguchi, H; Yaguchi, T | 1 |
| Okubo, A; Tsubouchi, I; Watanabe, S | 1 |
| Abe, M; Fujii, M; Fukuzawa, M; Hata, Y; Hattori, N; Iozumi, K; Ito, Y; Kasai, H; Katayama, I; Kato, F; Kato, I; Kiryu, H; Kodama, K; Kusuhara, M; Maruyama, R; Mayama, J; Mochizuki, T; Muramoto, F; Nakasu, I; Nishimoto, S; Nomiyama, T; Oh-I, T; Omi, T; Onoduka, T; Sato, T; Sei, Y; Seishima, M; Shimoyama, H; Shindo, M; Sugiura, K; Takahashi, H; Takeda, O; Takenaka, M; Tomizawa, K; Tsuboi, R; Uesugi, T; Watanabe, S; Yamamoto, O; Yamanaka, K; Yasuda, H | 1 |
| Malahias, S; Raterink, K; Sigurgeirsson, B; van Rossem, K | 1 |
| Rich, P | 2 |
| Tosti, A | 1 |
| Barbosa, NS; Wetter, DA | 1 |
| Lipner, S; Scher, RK | 1 |
| Elewski, BE; Gupta, AK; Ieda, C; Kang, R; Kawabata, H; Olin, JT; Pillai, R; Sugarman, JL; Watanabe, S | 1 |
| Pollak, RA | 1 |
| Al-Hatmi, AM; Bonifaz, A; Calderón, L; Curfs-Breuker, I; de Hoog, GS; Meis, JF; van Diepeningen, AD | 1 |
| Joseph, WS; Vlahovic, TC | 1 |
| Kawabata, H; Kodera, N; Pillai, R; Sakamoto, M; Sugimoto, N; Tatsumi, Y; Yamakawa, E | 1 |
| Elewski, BE; Olin, JT; Pillai, R; Pollak, RA | 1 |
| Bhatt, V; Pillai, R | 1 |
| Canavan, T; Cantrell, W; Elewski, B | 1 |
| Gupta, AK; Pillai, R | 1 |
| Jellinek, NJ; Korotzer, A | 1 |
| Lipner, SR; Scher, RK | 1 |
| Rosen, T | 1 |
| Dorval, E; Grace, Y; Machin, JD; Poulakos, M | 1 |
| Rosen, T; Stein Gold, LF | 3 |
| Lagrew, JP | 1 |
| Elewski, BE | 1 |
| Hiruma, M; Ihn, H; Kano, R; Matsumoto, T; Noguchi, H | 1 |
| Gupta, AK; Korotzer, A | 1 |
| Furuya, K; Hoshina, D; Yamaguchi, Y | 1 |
| Kawada, A; Oiso, N; Tatebayashi, M | 1 |
| Kimball, AB; Kumar, S | 1 |
| Blundell, CM; Greig, JM; Oddy, MJ; Suvarna, SK | 1 |
| Vera-Cabrera, L; Welsh, E; Welsh, O | 1 |
| Ashton, S; Elewski, B; Pollak, R; Rich, P; Schlessinger, J; Tavakkol, A | 1 |
| Elewski, BE; Ieda, C; Olin, JT; Pariser, DM; Pillai, R; Pollak, R; Ramakrishna, T; Rich, P; Senda, H; Smith, K; Watanabe, S | 1 |
| de Kerviler, E; Derouin, F; Feuilhade de Chavin, M; Lacroix, C; Morel, P | 1 |
| Conetta, B; Gupta, AK; Leonardi, C; Pierce, PF; Stoltz, RR | 1 |
| Selleslag, D | 1 |
| Sellart-Altisent, M; Torres-Rodríguez, JM | 1 |
| Dunand, J; Paugam, A | 1 |
9 review(s) available for triazoles and Foot Dermatoses
| Article | Year |
|---|---|
One size does not fit all: the need for individualized treatment based on factors that may affect the therapeutic outcome of efinaconazole 10% solution for the treatment of toenail onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Foot Dermatoses; Humans; Nails; Onychomycosis; Quality of Life; Treatment Outcome; Triazoles | 2021 |
The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials.
Topics: Administration, Topical; Aged; Antifungal Agents; Clinical Trials, Phase III as Topic; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Pharmaceutical Solutions; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Triazoles | 2014 |
Efinaconazole topical solution, 10%: the development of a new topical treatment for toenail onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Foot Dermatoses; Humans; Onychomycosis; Triazoles | 2014 |
Efinaconazole 10% topical solution for the topical treatment of onychomycosis of the toenail.
Topics: Administration, Topical; Animals; Antifungal Agents; Foot Dermatoses; Humans; Onychomycosis; Triazoles | 2015 |
Evaluation of gender as a clinically relevant outcome variable in the treatment of onychomycosis with efinaconazole topical solution 10.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prospective Studies; Randomized Controlled Trials as Topic; Sex Factors; Treatment Outcome; Triazoles; Young Adult | 2015 |
Efinaconazole and Tavaborole.
Topics: Administration, Topical; Animals; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Foot Dermatoses; Humans; Microbial Sensitivity Tests; Onychomycosis; Triazoles | 2017 |
Ungual hyalohyphomycosis caused by Fusarium proliferatum in an immunocompetent patient.
Topics: Administration, Topical; Aged; Antifungal Agents; Female; Foot Dermatoses; Fusariosis; Fusarium; Humans; Hyphae; Naphthalenes; Onychomycosis; Terbinafine; Triazoles | 2017 |
New antifungal therapies for the treatment of onychomycosis.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Drugs, Investigational; Foot Dermatoses; Hand Dermatoses; Humans; Microwaves; Onychomycosis; Photochemotherapy; Triazoles | 2009 |
Onychomycosis.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Ciclopirox; Drug Administration Schedule; Drug Therapy, Combination; Fluconazole; Foot Dermatoses; Humans; Itraconazole; Mitosporic Fungi; Morpholines; Naphthalenes; Onychomycosis; Pyridones; Pyrimidines; Terbinafine; Thiazoles; Triazoles; Voriconazole | 2010 |
21 trial(s) available for triazoles and Foot Dermatoses
| Article | Year |
|---|---|
Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Blood Glucose; Diabetes Complications; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles | 2020 |
Labeled use of efinaconazole topical solution 10% in treating onychomycosis in children and a review of the management of pediatric onychomycosis.
Topics: Administration, Topical; Adolescent; Antifungal Agents; Child; Foot Dermatoses; Humans; Multicenter Studies as Topic; Onychomycosis; Triazoles | 2020 |
Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study.
Topics: Administration, Cutaneous; Adolescent; Antifungal Agents; Child; Female; Foot Dermatoses; Humans; Male; Onychomycosis; Solutions; Treatment Outcome; Triazoles | 2021 |
Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients.
Topics: Administration, Topical; Adolescent; Antifungal Agents; Area Under Curve; Child; Female; Follow-Up Studies; Foot Dermatoses; Fungi; Humans; Male; Onychomycosis; Severity of Illness Index; Solutions; Treatment Outcome; Triazoles | 2020 |
Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis.
Topics: Administration, Cutaneous; Aged; Antifungal Agents; Drug Administration Schedule; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles | 2021 |
Is Severity of Disease a Prognostic Factor for Cure Following Treatment of Onychomycosis?
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prognosis; Severity of Illness Index; Treatment Outcome; Triazoles; Young Adult | 2018 |
Efficacy of combination therapy with efinaconazole 10% solution and 1064 nm Nd:YAG laser for treatment of toenail onychomycosis.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Combined Modality Therapy; Female; Follow-Up Studies; Foot Dermatoses; Humans; Laser Therapy; Lasers, Solid-State; Male; Middle Aged; Onychomycosis; Patient Satisfaction; Photography; Statistics, Nonparametric; Treatment Outcome; Triazoles | 2019 |
Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study.
Topics: Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prodrugs; Thiazoles; Treatment Outcome; Triazoles; Young Adult | 2018 |
Efficacy of long-term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases: A multicenter, single-arm study.
Topics: Administration, Topical; Aged; Antifungal Agents; Drug-Related Side Effects and Adverse Reactions; Female; Foot Dermatoses; Humans; Incidence; Long-Term Care; Male; Middle Aged; Onychomycosis; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles | 2019 |
A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis.
Topics: Administration, Oral; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Quinazolines; Time Factors; Treatment Outcome; Triazoles; Young Adult | 2013 |
Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Diabetes Mellitus; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles | 2014 |
Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Drug Delivery Systems; Female; Follow-Up Studies; Foot Dermatoses; Humans; In Vitro Techniques; Male; Microbial Sensitivity Tests; Middle Aged; Nails; Onychomycosis; Permeability; Triazoles; Trichophyton | 2014 |
Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space.
Topics: Administration, Topical; Antifungal Agents; Female; Foot Dermatoses; Humans; Male; Middle Aged; Nails; Onychomycosis; Permeability; Treatment Outcome; Triazoles | 2014 |
Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early.
Topics: Administration, Topical; Adult; Antifungal Agents; Disease Progression; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prospective Studies; Time Factors; Treatment Outcome; Triazoles | 2015 |
The Presence of an Air Gap Between the Nail Plate and Nail Bed in Onychomycosis Patients: Treatment Implications for Topical Therapy.
Topics: Administration, Cutaneous; Adult; Aged; Air; Antifungal Agents; Female; Fluorescein; Foot Dermatoses; Humans; Male; Middle Aged; Nails; Onychomycosis; Pharmaceutical Vehicles; Severity of Illness Index; Triazoles | 2015 |
Prognostic Factors for Complete Cure Following Treatment of Mild and Moderate Toenail Onychomycosis With Efinaconazole Topical Solution 10.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prognosis; Severity of Illness Index; Treatment Outcome; Triazoles; Young Adult | 2015 |
A financial perspective on the topical treatment of onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Female; Follow-Up Studies; Foot Dermatoses; Humans; Male; Onychomycosis; Risk Assessment; Treatment Outcome; Triazoles | 2016 |
Topical Treatment of Onychomycosis and Clinically Meaningful Outcomes.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Follow-Up Studies; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles; Young Adult | 2016 |
A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Drug Administration Schedule; Female; Foot Dermatoses; Humans; Male; Middle Aged; Naphthalenes; Onychomycosis; Tablets; Terbinafine; Treatment Outcome; Triazoles; Young Adult | 2012 |
Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Triazoles; Young Adult | 2013 |
A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Double-Blind Method; Drug Administration Schedule; Foot Dermatoses; France; Humans; Nails; Ontario; Onychomycosis; Severity of Illness Index; Thiazoles; Treatment Outcome; Triazoles; United States | 2005 |
26 other study(ies) available for triazoles and Foot Dermatoses
| Article | Year |
|---|---|
Total Dystrophic Onychomycosis Successfully Treated with Efinaconazole Topical Solution in Times of Coronavirus Disease of 2019: A Case Study.
Topics: Administration, Topical; Adult; Antifungal Agents; Coronavirus; Female; Foot Dermatoses; Humans; Onychomycosis; Treatment Outcome; Triazoles | 2022 |
Onychomycosis Caused by Talaromyces muroii Successfully Treated with Efinaconazole.
Topics: Administration, Topical; Antifungal Agents; Foot Dermatoses; Humans; Onychomycosis; Talaromyces; Triazoles | 2023 |
Modeling of usage and estimation of cost for efinaconazole 10% topical solution in the treatment of onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Drug Costs; Foot Dermatoses; Healthy Volunteers; Humans; Nails; Onychomycosis; Solutions; Triazoles; United States | 2020 |
Contact Dermatitis Caused by Efinaconazole and Luliconazole.
Topics: Administration, Topical; Aged; Antifungal Agents; Dermatitis, Contact; Epitopes; Foot Dermatoses; Humans; Imidazoles; Male; Patch Tests; Triazoles | 2021 |
JUBLIA (Efinaconazole 10% Solution) in the Treatment of Pediatric Onychomycosis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Child; Foot Dermatoses; Humans; Onychomycosis; Terbinafine; Triazoles | 2021 |
Efinaconazole solution 10% for treatment of toenail onychomycosis in Latino patients.
Topics: Administration, Topical; Antifungal Agents; Female; Foot Dermatoses; Hispanic or Latino; Humans; Male; Middle Aged; Onychomycosis; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles; United States | 2017 |
Topical efinaconazole: A promising therapeutic medication for tinea unguium.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifungal Agents; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Photography; Treatment Outcome; Triazoles | 2018 |
Onychomycosis caused by Aspergillus subramanianii.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Antifungal Agents; Aspergillosis; Aspergillus; Female; Foot Dermatoses; Humans; Hyphae; Japan; Microscopy; Onychomycosis; Terbinafine; Triazoles; Young Adult | 2018 |
Topical treatment of onychomycosis with efinaconazole solution 10%.
Topics: Adult; Antifungal Agents; Foot Dermatoses; Humans; Male; Onychomycosis; Triazoles; Trichophyton | 2013 |
Efinaconazole solution 10%: topical antifungal therapy for toenail onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Foot Dermatoses; Humans; Onychomycosis; Recurrence; Triazoles | 2013 |
Bullous phototoxicity from voriconazole.
Topics: Adult; Antifungal Agents; Dermatitis, Phototoxic; Drug Eruptions; Female; Foot Dermatoses; Humans; Pyrimidines; Skin Diseases, Vesiculobullous; Sunbathing; Triazoles; Voriconazole | 2014 |
Onychomycosis: current and future therapies.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Debridement; Foot Dermatoses; Hand Dermatoses; Humans; Laser Therapy; Morpholines; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Triazoles | 2014 |
Proximal subungual onychomycosis caused by Fusarium falciforme successfully cured with posaconazole.
Topics: Antifungal Agents; Foot Dermatoses; Fusariosis; Fusarium; Humans; Male; Middle Aged; Molecular Sequence Data; Onychomycosis; Triazoles | 2015 |
Efinaconazole topical solution, 10%: formulation development program of a new topical treatment of toenail onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Chemistry, Pharmaceutical; Drug Delivery Systems; Foot Dermatoses; Humans; Nail Diseases; Nails; Onychomycosis; Permeability; Pharmaceutical Solutions; Solubility; Triazoles | 2015 |
Report of a case of a dermatophytoma successfully treated with topical efinaconazole 10% solution.
Topics: Administration, Topical; Aged; Antifungal Agents; Foot Dermatoses; Humans; Male; Naphthalenes; Onychomycosis; Terbinafine; Tinea; Treatment Outcome; Triazoles | 2015 |
Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Fluconazole; Foot Dermatoses; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Treatment Outcome; Triazoles; United States | 2016 |
Introduction.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Foot Dermatoses; Humans; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Treatment Outcome; Triazoles | 2016 |
Using Topical Antifungal Medications: Instructions for patients.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Drug Administration Schedule; Foot Dermatoses; Humans; Onychomycosis; Pyridones; Triazoles | 2016 |
Response to "A financial perspective on the topical treatment of onychomycosis".
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Drug Costs; Female; Foot Dermatoses; Humans; Male; Onychomycosis; Sensitivity and Specificity; Severity of Illness Index; Triazoles | 2016 |
Onychomadesis caused by efinaconazole.
Topics: Administration, Topical; Aged; Antifungal Agents; Dermatitis, Allergic Contact; Foot Dermatoses; Humans; Male; Nail Diseases; Onychomycosis; Patch Tests; Triazoles | 2017 |
Allergic contact dermatitis caused by efinaconazole: positive patch test reactions up to 0.1% pet.
Topics: Administration, Topical; Aged; Antifungal Agents; Dermatitis, Allergic Contact; Foot Dermatoses; Humans; Male; Onychomycosis; Patch Tests; Triazoles | 2017 |
Mycetoma of the foot.
Topics: Adult; Antifungal Agents; Female; Foot Dermatoses; Humans; Madurella; Magnetic Resonance Imaging; Mycetoma; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole; Young Adult | 2009 |
Madurella mycetomatis mycetoma treated successfully with oral voriconazole.
Topics: Administration, Oral; Adult; Antifungal Agents; Foot Dermatoses; Humans; Magnetic Resonance Imaging; Male; Mycetoma; Pyrimidines; Triazoles; Voriconazole | 2005 |
A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B.
Topics: Abscess; Amphotericin B; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytarabine; Foot Dermatoses; Fusarium; Humans; Imatinib Mesylate; Immunocompromised Host; Liposomes; Male; Middle Aged; Muscular Diseases; Onychomycosis; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Reoperation; Rituximab; Teniposide; Triazoles; Voriconazole | 2006 |
[Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani].
Topics: Antifungal Agents; Cellulitis; Ciclopirox; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Resistance, Multiple, Fungal; Foot Dermatoses; Fusarium; Humans; Imidazoles; Immunocompetence; Itraconazole; Male; Middle Aged; Mozambique; Onychomycosis; Pyridones; Pyrimidines; Recurrence; Toes; Travel; Triazoles; Urea; Voriconazole | 2006 |
[In vitro susceptibility of isolates of Scytalidium spp. from superficial lesions against posaconazole].
Topics: Antifungal Agents; Ascomycota; Dermatomycoses; Drug Resistance, Fungal; Foot Dermatoses; Humans; Microbial Sensitivity Tests; Mitosporic Fungi; Onychomycosis; Triazoles | 2008 |